Welcome to our dedicated page for JanOne news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JanOne stock.
The news page for JanOne Inc. (historically Nasdaq: JAN) provides an archive of company announcements and press releases that document its transition into ALT5 Sigma Corporation and the evolution of its business focus. These news items explain how the organization moved from being described primarily as a biopharmaceutical company focused on non-addicting pain treatments to a multidisciplinary entity combining healthcare initiatives with a growing fintech platform centered on blockchain-powered digital asset services.
Readers will find coverage of the company’s confirmation of its name change to ALT5 Sigma Corporation and ticker change to ALTS, reflecting a strategic realignment to focus on its recently acquired ALT5 Sigma fintech business as a core engine for revenue growth. News articles describe the acquisition and integration of ALT5 Sigma Inc., the company’s addition to the Russell Microcap Index, and subsequent developments such as the launch of the ALT5 Settlement Platform, the introduction of a prepaid Visa card integration, and reported transaction volumes processed by ALT5 subsidiaries.
The archive also includes updates on leadership appointments related to the fintech business, such as the naming of a Chief Revenue Officer and President for ALT5 Sigma, as well as communications about the company’s ongoing biotech activities aimed at addressing the opioid crisis. Earlier releases highlight JanOne’s efforts to develop non-addicting pain treatments and its dedication to funding innovation, technology, and education in this area.
By reviewing the JAN news feed, investors and researchers can trace key milestones, including the acquisition of ALT5 Sigma, strategic realignment decisions, and subsequent product and platform launches in digital payments and digital asset trading. Because the active Nasdaq ticker has changed from JAN to ALTS, this page serves as a historical record of announcements made under the JAN symbol, complementing more recent disclosures filed under the ALT5 Sigma Corporation identity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
JanOne (NASDAQ: JAN) announced a successful pre-IND meeting with the FDA on April 18, 2023, regarding Jan123, a low dose naltrexone aimed at treating complex regional pain syndrome (CRPS). This rare disease causes severe pain and has no current cure. The FDA's feedback gives JanOne a pathway for submitting a New Drug Application under the 505(b)(2) designation. Key discussion points included preclinical toxicology and clinical implementation, which are crucial for progressing Jan123 towards formal approval. Both JanOne's Chief Medical Officer and CEO expressed optimism about the therapeutic potential of Jan123 and its role in addressing the opioid crisis. The company emphasizes its commitment to innovative pain management solutions.
JanOne (Nasdaq: JAN), represented by Dr. Amol Soin, will present at the Appalachian Region Spine and Pain Meeting on April 15, 2023, discussing innovation in pain medicine and the company’s drug development programs. JanOne focuses on non-opioid treatments for pain management, introducing two late-stage drug candidates: JAN 101, aimed at treating peripheral artery disease and diabetic neuropathy, and JAN 123, a low-dose naltrexone for Complex Regional Pain Syndrome, which received orphan drug status from the FDA. Dr. Soin aims to highlight the need for effective pain management solutions amid the opioid crisis, which underscores JanOne's commitment to developing non-addictive medication options. The meeting will serve as a platform to engage physicians seeking alternatives to opioids.
JanOne, a biopharmaceutical company on Nasdaq (JAN), announced the appointment of John N. Bonfiglio, PhD, as the interim president of its subsidiary, JanOne Biotech. His extensive background in leading successful biotech firms includes raising over